Found: 534
Select item for more details and to access through your institution.
Racial disparities in hospitalization outcomes among adult multiple myeloma patients using the national inpatient sample (2016–2018).
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 724, doi. 10.1002/hon.2907
- By:
- Publication type:
- Article
Implication of immune cell signature of tumor microenvironment in diffuse large B‐cell lymphoma.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 616, doi. 10.1002/hon.2905
- By:
- Publication type:
- Article
Secondary primary malignancies in patients with multiple myeloma: A single institution experience.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 674, doi. 10.1002/hon.2923
- By:
- Publication type:
- Article
Outcomes of hematopoietic cell transplantation for transformed follicular lymphoma.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 650, doi. 10.1002/hon.2917
- By:
- Publication type:
- Article
Successful early treatment combining remdesivir with high‐titer convalescent plasma among COVID‐19‐infected hematological patients.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 715, doi. 10.1002/hon.2908
- By:
- Publication type:
- Article
The resistance mechanisms and treatment strategies of BTK inhibitors in B‐cell lymphoma.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 605, doi. 10.1002/hon.2933
- By:
- Publication type:
- Article
A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 595, doi. 10.1002/hon.2929
- By:
- Publication type:
- Article
Combined tumor‐associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 625, doi. 10.1002/hon.2926
- By:
- Publication type:
- Article
Hypoalbuminemia as a prognostic biomarker for higher mortality and treatment complications in acute myeloid leukemia.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 697, doi. 10.1002/hon.2925
- By:
- Publication type:
- Article
Comparison of first‐line treatments of peripheral T‐cell lymphoma according to regimen: A systematic review and meta‐analysis.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 664, doi. 10.1002/hon.2924
- By:
- Publication type:
- Article
Lower incidence of clinical allergy with PEG‐asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG‐ASP in pediatric patients with acute lymphoblastic leukemia.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 687, doi. 10.1002/hon.2914
- By:
- Publication type:
- Article
Prognostic ability of five clinical risk scores in follicular lymphoma: A single‐center evaluation.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 639, doi. 10.1002/hon.2922
- By:
- Publication type:
- Article
On the relevance of immunodeficiency evaluation in haematological cancer.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 721, doi. 10.1002/hon.2921
- By:
- Publication type:
- Article
Outcomes in primary cutaneous diffuse large B‐cell lymphoma, leg type.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 658, doi. 10.1002/hon.2919
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 593, doi. 10.1002/hon.2749
- Publication type:
- Article
COVID‐19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 712, doi. 10.1002/hon.2916
- By:
- Publication type:
- Article
IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 707, doi. 10.1002/hon.2915
- By:
- Publication type:
- Article
Outcomes and prognostic factors of adults with refractory or relapsed T‐cell acute lymphoblastic leukemia included in measurable residual disease‐oriented trials.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 529, doi. 10.1002/hon.2910
- By:
- Publication type:
- Article
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia‐positive acute lymphoblastic leukaemia.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 680, doi. 10.1002/hon.2913
- By:
- Publication type:
- Article
Is race important in genomic classification of hematological neoplasms?
- Published in:
- Hematological Oncology, 2021, v. 39, n. 5, p. 728, doi. 10.1002/hon.2909
- By:
- Publication type:
- Article
Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 521, doi. 10.1002/hon.2906
- By:
- Publication type:
- Article
CD38 expression is an important prognostic marker in diffuse large B‐cell lymphoma.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 483, doi. 10.1002/hon.2904
- By:
- Publication type:
- Article
Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 589, doi. 10.1002/hon.2903
- By:
- Publication type:
- Article
Impact of initial chemotherapy regimen on outcomes for patients with double‐expressor lymphoma: A multi‐center analysis.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 473, doi. 10.1002/hon.2902
- By:
- Publication type:
- Article
RBCK1‐TRIB3 decelerated the progression of acute promyelocytic leukemia.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 567, doi. 10.1002/hon.2901
- By:
- Publication type:
- Article
Erratum.
- Published in:
- 2021
- Publication type:
- Correction Notice
Erratum.
- Published in:
- 2021
- Publication type:
- Correction Notice
Immunoglobulin replacement therapy discontinuation in patients with antibody deficiency secondary to hematological malignancy.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 584, doi. 10.1002/hon.2900
- By:
- Publication type:
- Article
Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 498, doi. 10.1002/hon.2897
- By:
- Publication type:
- Article
Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 549, doi. 10.1002/hon.2896
- By:
- Publication type:
- Article
Issue Information.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 437, doi. 10.1002/hon.2748
- Publication type:
- Article
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 570, doi. 10.1002/hon.2899
- By:
- Publication type:
- Article
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 558, doi. 10.1002/hon.2898
- By:
- Publication type:
- Article
Circ_0009910 shuttled by exosomes regulates proliferation, cell cycle and apoptosis of acute myeloid leukemia cells by regulating miR‐5195‐3p/GRB10 axis.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 390, doi. 10.1002/hon.2874
- By:
- Publication type:
- Article
Downregulation of circ_0012152 inhibits proliferation and induces apoptosis in acute myeloid leukemia cells through the miR‐625‐5p/SOX12 axis.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 539, doi. 10.1002/hon.2895
- By:
- Publication type:
- Article
Intrahospital COVID‐19 infection outbreak management: Keep calm and carry on.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 431, doi. 10.1002/hon.2873
- By:
- Publication type:
- Article
Lenalidomide abrogates the survival effect of bone marrow stromal cells in chronic lymphocytic leukemia.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 513, doi. 10.1002/hon.2888
- By:
- Publication type:
- Article
Perirenal and subcutaneous fat differently affect outcomes in newly diagnosed classical Hodgkin lymphoma patients.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 580, doi. 10.1002/hon.2886
- By:
- Publication type:
- Article
Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and meta‐analysis.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 448, doi. 10.1002/hon.2875
- By:
- Publication type:
- Article
Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B‐cell lymphomas.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 465, doi. 10.1002/hon.2871
- By:
- Publication type:
- Article
Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B‐cell lymphoma in the rituximab era.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 490, doi. 10.1002/hon.2869
- By:
- Publication type:
- Article
Hepatitis C virus‐associated indolent B‐cell lymphomas: A review on the role of the new direct antiviral agents therapy.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 439, doi. 10.1002/hon.2862
- By:
- Publication type:
- Article
Long‐term follow‐up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 4, p. 506, doi. 10.1002/hon.2835
- By:
- Publication type:
- Article
Low grade, indolent lymphomas of the head and neck: Comparative toxicity of standard versus very low dose radiation therapy.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 304, doi. 10.1002/hon.2865
- By:
- Publication type:
- Article
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 293, doi. 10.1002/hon.2864
- By:
- Publication type:
- Article
Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomas.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 336, doi. 10.1002/hon.2842
- By:
- Publication type:
- Article
FZD6 triggers Wnt–signalling driven by WNT10B<sup>IVS1</sup> expression and highlights new targets in T‐cell acute lymphoblastic leukemia.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 364, doi. 10.1002/hon.2840
- By:
- Publication type:
- Article
Seroconversion and kinetic of anti SARS‐COV‐2 antibodies in 25 patients with hematological malignancies who recovered from SARS‐COV‐2 infection.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 428, doi. 10.1002/hon.2872
- By:
- Publication type:
- Article
Rare lymphomas in routine practice – Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
- Published in:
- Hematological Oncology, 2021, v. 39, n. 3, p. 313, doi. 10.1002/hon.2868
- By:
- Publication type:
- Article